Six thousand Americans. More than 24,000 stool samples. One question: can what you feed your gut calm your mind?
On October 8, Holobiome and Radicle Science launched GUT-FEELINGS, a two-year research initiative backed by the Advanced Research Projects Agency for Health (ARPA-H), the federal agency that funds high-risk, high-reward health science. Over 6,000 diverse Americans will enroll in two waves, making it the largest mental-wellness trial in U.S. history – and the first at this scale aimed squarely at the gut-brain axis.
The central question is refreshingly practical: can food-derived prebiotic formulas – the kind you could buy without a prescription – measurably improve feelings of anxiety and related mental wellness? And if so, for whom?
A tournament, not a duel
Here’s the scale. The 16-week study randomizes people who experience feelings of anxiety into 20 arms: 19 distinct proprietary prebiotic formulations, plus placebo. Nineteen interventions tested head-to-head in a single trial is unusual. Most studies pit one thing against one control. This one runs more like a tournament bracket.
The measurement goes far beyond questionnaires, though the trial does track validated anxiety measures along with stress, mood, sleep, quality of life, flourishing, weight, waist measurements, and diet quality. Reported outcomes are paired with deep biological and digital data: ultra-deep fecal microbiome sequencing and metabolomics, blood proteomics, wearable data, facial scans, and continuous glucose monitoring. The final tally: over 24,000 fecal samples and 12,000 blood samples.
It’s decentralized and tech-enabled – participants contribute from home instead of traveling to clinics – which is how you enroll 6,000 people without building a 6,000-person waiting room. Initial results are expected in the second half of 2027.
Why the gut-brain axis is having its moment
The gut and brain talk constantly – through the vagus nerve, through immune signaling, and through the vast microbial ecosystem of the digestive tract. The idea that gut microbes influence mood has moved from fringe to frontier, with a growing stack of animal studies and smaller human trials behind it. What’s been missing is the kind of large, rigorous, head-to-head evidence that turns a promising idea into clinical guidance.
That’s exactly what GUT-FEELINGS is built to deliver. Because 19 formulas are tested in parallel against placebo, researchers can answer not just “does it work” but “which formulations work, and in which populations.” The gut microbiome varies enormously between people, and one of the trial’s explicit goals is to learn which interventions help which kinds of people – a first step toward personalized mental-wellness nutrition.
The bigger play: a foundation model of the gut
All that biological data has a second destination. Holobiome plans to use the dataset to build “Mercator,” a foundation model of the human gut microbiome – the microbial equivalent of the large language models that transformed AI. The goal: a model that understands how the gut microbiome interfaces with biology relevant to mental wellness and beyond, informing the next generation of probiotic and prebiotic development.
If you follow health tech, you’ll recognize the pattern. Massive datasets are turning fuzzy biological questions into tractable computational ones. The gut-brain axis sits right at the center of that shift.
Keeping expectations honest
First, the reality check: this is a launch, not a result. Nobody should buy prebiotics expecting a clinical outcome on the strength of a trial announcement. The results arrive in late 2027. Until then, the responsible move is to watch and wait.
Second, the structure of the answer matters. If GUT-FEELINGS succeeds, it won’t produce a single “anxiety supplement.” It will produce a map: which formulations, for which microbiome profiles, with what size of effect. That’s a more useful outcome – and a harder one to hype.
Third, there’s the access angle. The trial is explicitly hunting for “readily deployable” solutions – things that work without a prescription. If the evidence lands, mental-wellness support could become cheaper and more accessible than it is today, which matters when therapy and medication remain out of reach for millions of people.
Anxiety is one of the most common conditions in the country, and the toolkit for addressing it has been slow to grow. Now a federal research agency has made it one of its biggest bets, thousands of “citizen scientists” are generating real-world evidence, and the endpoint isn’t just the absence of symptoms – it’s flourishing. That’s worth paying attention to.
Be First to Comment